... Second Wound Ambulance Established in Monterrey ...MONTERREY Mexico and WITTEN Germany December 4FirstCa...State health authorities support approval and practical use of woundm...Submitted were letters of the State Ministry of Health of the Mexican...

MONTERREY, Mexico, and WITTEN, Germany, December 4
/PRNewswire-FirstCall/ -- Sangui Latino America and Sangui BioTech GmbH
executives jointly opened another wound management ambulance in the center
of Monterrey, Mexico, on the occasion of a three day working visit. Sangui
BioTech GmbH Managing Director Hubertus Schmelz and Sangui Marketing
Representative Renate Pentzien discussed the next steps of the successful
cooperation of the two companies with the Mexican partners. An enlarged
series of cosmetics presented by Renate Pentzien on this occasion met
considerable interest.

State health authorities support approval and practical use of wound
management products

Submitted were letters of the State Ministry of Health of the Mexican
state of Tamaulipas. In those letters the health authorities underscore
their support of both, the further wound management projects as well as the
planned preclinical and clinical tests aiming at the approval of Sangui's
blood additive. Starting early in 2008, clinical studies will be carried
out at the General Hospital of Ciudad Victoria, Tamaulipas' capital, using
Sangui's wound management products (Scabremove for wound debridement, the
Hemospray wound spray and the Chitoskin wound pad) on another 30 patients
suffering from chronic wounds. In charge of the studies will be specialist
doctors at this hospital in cooperation with Sangui medical staff. It is
being anticipated that the studies will be accomplished in the course of
the first half of 2008.

According to additional information provided by Sangui Latino America,
a health authority approval of the Sangui products as medical products will
be available shortly after the successful accomplishment of this study.
Moreover, Sangui Latino America indicated that the State of Tamaulipas
intends to make comprehensive practical use of Sangui's products in
hospitals and medical institutions under its responsibility.

Both companies appreciated this official commitment as the most
important result of their cooperation so far. It underlines the succes of
the therapeutic work carried out in the private ambulances, which
completely yielded the expected healing results. According to the Mexican
partners, a medical products approval by the Tamaulipas State Ministry will
immediately put Sangui in the position to service not only the Mexican but
also the entire Latin American market.

Mexico counts approximately 17 million diabetes II patients, the care
and therapy of whom consumes more than 30% of the Mexican health budget -
at a still increasing percentage. Other reasons for the occurrence of
chronic wounds include ulcus cruris or amputations, all of which are
eligible for treatments with Sangui products. Clinical data obtained in
Mexico will be beneficial also for the EU approval process, which continues
to be on schedule.

Definite planning starts for blood additive project

The Tamaulipas State Ministry has additionally declared its
comprehensive support for the blood additive project including in
particular the preclinical and clinical studies. Sangui Latino America and
Sangui BioTech GmbH, therefore, have started definite planning aimed at the
fastest and most efficient ways to carry out this key project. The
respective planning how to produce the test substance needed for the
preclinical testing has already been completed. Currently, the favourite
option is to establish the production facility in the existing clean rooms
of Sangui BioTech in Witten, Germany. The test design describing the
toxicological as well as pharmacological tests of the preclinical phase
will be written in close cooperation with the authorities in Ciudad
Victoria. Starting immediately, test designs for possible clinical studies
will be elaborated in mutual understanding of all parties involved. The
target is to identify and weigh different possible indications including in
particular heart attack and lung shock. It is the common understanding of
the partners to look at a project start in the course of the first half of
2008.

The two companies in Germany and Mexico which are not affiliated
legally have established a trustful partnership which now becomes
increasingly closer.

Hubertus Schmelz underscores, therefore: "We are very satisfied with
the course things in Mexico are now taking thanks to the energy of our
partners. Their commitment, their willingness to invest and their
determination are paramount examples for the industry. They allowed our
wound management products to show in a large number of patients that they
actually work the way we expected them to. Based on the test results
obtained so far we expect that we will be able to accomplish the additional
30 patient study successfully and at short notice. The entailing official
approval as medical products would give us access to important and large
markets. And, we are particularly excited about the prospects for the blood
additive - as this key venture of our company will enter definite planning
and roll-out at last. We are more than grateful for our partners in Mexico.
It is their strong commitment which makes all this fast progress happen."

The joint prospects are being confirmed by Sangui Latino America
President Eduardo Mena: "In the past couple of months, we have been able to
convince ourselves that Sangui's wound management products and concepts do
keep what they promise. We are determined, therefore, to further extend our
commitment and to take the necessary steps towards product approval in
close accordance with the Tamaulipas authorities. Jointly also we shall
proceed with the blood additive project, as we consider it a product which
will eventually help treating severly ill patients and even save their
lives. We are well aware of the financial requirements, but we are deeply
convinced that this is an investment which will pay back."

Some of the statements contained in this news release discuss future
expectations, contain projections of results of operation or financial
condition or state other "forward-looking" information. These statements
are subject to known and unknown risks, uncertainties, and other factors
that could cause the actual results to differ materially from those
contemplated by the statements. The forward-looking information is based on
various factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections include,
among many others, the ability of the Company to raise sufficient capital
to meet operating requirements. Words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," and variations of
such words and similar expressions are intended to identify such
forward-looking statements. Unless required by law, the Company undertakes
no obligation to update publicly any forward-looking statements, whether as
a result of new information, future events or otherwise.

(Date:12/8/2016)... CA (PRWEB) , ... December 08, 2016 , ... Lajollacooks4u, ... was a banner year for team building events, new program offerings and company expansion. ... it expanded earlier this year to include groups of over 30 people. Ever since, ...

(Date:12/8/2016)... Biotheranostics today announced that new data will ... Cancer Index (BCI) in identifying which patients with ... for disease recurrence and might benefit from extended ... advancing the understanding of the value of BCI ... inform decisions related to patient treatment. These data ...

(Date:11/21/2016)... Lithuania , Nov. 21, 2016 ... and object recognition technologies, today announced that the ... smart cards was submitted for the NIST ... successfully passed all the mandatory steps of the ... evaluation is a continuing test of fingerprint templates ...

(Date:11/15/2016)... Nov. 15, 2016 Synthetic Biologics, Inc. (NYSE ... focused on the gut microbiome, today announced the ... shares of its common stock and warrants to ... a price to the public of $1.00 per ... Biologics from the offering, excluding the proceeds, if ...